These findings suggested that the TP53 G:C > T:A transversion mutation in Rwandan patients with gastric cancer was more frequent than in non-Rwandan patients with gastric cancer, probably due to a different etiological and carcinogenic process of gastric cancer in Rwanda. This evidence concerns the gene TP53 and gastric cancer.